Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.

Jindan ShengSusumu KohnoNobuhiro OkadaNobuyuki OkahashiKana TeranishiFumio MatsudaHiroshi ShimizuPaing LinnNaoko NagataniMinako YamamuraKenichi HaradaShin-Ichi HorikeHiroshi InoueSeiji YanoSharad KumarShunsuke KitajimaItsuki AjiokaChiaki Takahashi

Published in: Hepatology (Baltimore, Md.) (2021)

In conclusion, CDK4/6 inhibitors have a potential to treat a wide variety of RB1-intact cancers including HCC when combined with an appropriate kinase inhibitor.

Keyphrases

combination therapy
cell cycle
young adults
cell death
cell proliferation
smoking cessation